Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$17.7MFederal grants as PI29 awards
1Patents grantedLatest Feb 26, 2019
37Papers566 citations
Federal awards and patents by year
AwardsPatents
29 awards · $17.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 30, 2025 | NIH | SBIR Phase II Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $1000K | VIVREON BIOSCIENCES LLC |
| Jul 8, 2025 | NIH | SBIR Phase II Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $1.1M | VIVREON BIOSCIENCES LLC |
| Aug 28, 2024 | NIH | SBIR Phase I Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies | $307K | VIVREON BIOSCIENCES LLC |
| Aug 1, 2024 | NIH | SBIR Phase II Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $1000K | VIVREON BIOSCIENCES LLC |
| Jul 9, 2024 | NIH | SBIR Phase II Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $1.4M | VIVREON BIOSCIENCES LLC |
| May 21, 2024 | NIH | SBIR Phase II IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $502K | VIVREON BIOSCIENCES LLC |
| Jul 28, 2023 | NIH | SBIR Phase II Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $50K | VIVREON BIOSCIENCES LLC |
| Jul 6, 2023 | NIH | SBIR Phase II Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | $320K | VIVREON BIOSCIENCES LLC |
| May 15, 2023 | NIH | SBIR Phase II Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1.2M | VIVREON BIOSCIENCES LLC |
| Apr 10, 2023 | NIH | SBIR Phase I Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma | $352K | VIVREON BIOSCIENCES LLC |
| Sep 14, 2022 | NIH | SBIR Phase II Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1.3M | VIVREON BIOSCIENCES LLC |
| Sep 8, 2022 | NIH | SBIR Phase I Development of a Novel CRAC Channel Therapeutic for the Treatment of Primary Hyperhidrosis | $245K | VIVREON BIOSCIENCES LLC |
| May 31, 2022 | NIH | SBIR Phase II IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $1.4M | VIVREON BIOSCIENCES LLC |
| Apr 21, 2022 | NIH | SBIR Phase I Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | $300K | VIVREON BIOSCIENCES LLC |
| Sep 23, 2021 | NIH | SBIR Phase I Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis | $252K | VIVREON BIOSCIENCES LLC |
| Apr 19, 2021 | NIH | SBIR Phase I Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | $55K | VIVREON BIOSCIENCES LLC |
| Feb 17, 2021 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $193K | VIVREON BIOSCIENCES LLC |
| Sep 22, 2020 | NIH | SBIR Phase I Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | $350K | VIVREON BIOSCIENCES LLC |
| Aug 21, 2020 | NIH | SBIR Phase II Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $250K | VIVREON BIOSCIENCES LLC |
| May 20, 2020 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1.2M | VIVREON BIOSCIENCES LLC |
| Apr 29, 2020 | NIH | SBIR Phase II Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $225K | VIVREON BIOSCIENCES LLC |
| Aug 27, 2019 | NIH | SBIR Phase II Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $1.0M | VIVREON BIOSCIENCES LLC |
| Jul 26, 2019 | NIH | SBIR Phase I Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $271K | VIVREON BIOSCIENCES LLC |
| Jun 6, 2019 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $1.3M | VIVREON BIOSCIENCES LLC |
| Jun 11, 2018 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $746K | VIVREON BIOSCIENCES LLC |
| Mar 2, 2018 | NIH | SBIR Phase I Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | $225K | VIVREON BIOSCIENCES LLC |
| Jul 24, 2017 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $746K | VIVREON BIOSCIENCES LLC |
| Jun 23, 2017 | NIH | SBIR Phase I Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis | $220K | VIVREON BIOSCIENCES LLC |
| Sep 15, 2016 | NIH | SBIR Phase II Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | $222K | VIVREON BIOSCIENCES LLC |
2 patents as inventor
- US 10213412VIVREON BIOSCIENCES LLCFeb 26, 2019
- US VIVREON BIOSCIENCES LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#11
Awards as PI#7
Patents#155
Companies
- VIVREON BIOSCIENCES LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.